Landos Biopharma (NASDAQ:LABP) Shares Down 0.2%

Landos Biopharma, Inc. (NASDAQ:LABP)’s share price traded down 0.2% during trading on Thursday . The stock traded as low as $21.91 and last traded at $22.25. 6,316 shares traded hands during mid-day trading, a decline of 70% from the average session volume of 20,962 shares. The stock had previously closed at $22.29.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $20.42 price target (down previously from $50.00) on shares of Landos Biopharma in a research note on Monday, April 1st.

Landos Biopharma Stock Performance

The company has a 50 day moving average price of $15.72 and a 200 day moving average price of $8.33. The firm has a market cap of $69.37 million, a price-to-earnings ratio of -6.43 and a beta of 0.14.

Landos Biopharma (NASDAQ:LABP) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.08). On average, research analysts forecast that Landos Biopharma, Inc. will post -2.19 earnings per share for the current year.

Institutional Trading of Landos Biopharma

An institutional investor recently bought a new position in Landos Biopharma stock. Deltec Asset Management LLC acquired a new stake in shares of Landos Biopharma, Inc. (NASDAQ:LABP) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 50,000 shares of the company’s stock, valued at approximately $1,074,000. Deltec Asset Management LLC owned about 1.60% of Landos Biopharma as of its most recent SEC filing. Institutional investors and hedge funds own 49.06% of the company’s stock.

Landos Biopharma Company Profile

Landos Biopharma, Inc, a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract.